Antimicrobial resistance is a silent pandemic. Examine how India's drug scheduling regime addresses this challenge.

Antimicrobial resistance (AMR) is driven by the overuse and misuse of antimicrobials in humans, animals and agriculture [1]. India's principal legal lever at the point of sale is the Schedule system under the Drugs Rules, 1945, framed under the Drugs and Cosmetics Act, 1940 — a necessary, but only partial, line of defence.

How the scheduling regime confronts AMR

• Prescription gatekeeping: drugs under Schedule H and Schedule X may be sold by retail only on a Registered Medical Practitioner's prescription [2].
• Schedule H1 (GSR 588(E), 30 August 2013; effective 1 March 2014) targets AMR directly — covering third and fourth generation antibiotics, anti-TB and habit-forming drugs, with a red Rx label and a separate sale register recording prescriber, patient, drug and quantity, retained three years and open to inspection [2].
• A dynamic list: in July 2026, formulations above 12% v/v ethyl alcohol exceeding 30 mL were moved out of the Schedule K exemption into Schedule H1 [3].
• Continuing tightening: restrictions on advertising Schedule H, H1 and X drugs, and a draft amendment proposing CCTV surveillance at retail chemist outlets [4].

Where it falls short

• Enforcement, not rule-making, is the gap: the H1 register has existed since 2014, yet over-the-counter antibiotic dispensing persists. A camera records; it does not inspect.
• Capacity deficit: the Mashelkar Committee (2003) sought a stronger drug regulatory system, but the Drugs and Cosmetics (Amendment) Bills of 2005 and 2007 did not address strengthening regulation at the state level [5] — where chemist licensing and inspection actually sit.
• Sale-side tool only: physician overprescription and antimicrobial use in animals and agriculture lie wholly outside these Rules [1].
• Access friction: in underserved districts, a hard prescription rule may push patients toward quacks or incomplete courses.

Scheduling is thus a sharp but narrow instrument. Its promise is realised only when paired with state drug-inspectorate capacity, the National Action Plan on AMR's One Health approach, prescriber stewardship and public awareness — sequencing enforcement with prescriber availability so the lawful path is also the easy one. So calibrated, the regime can advance SDG 3 and make India's answer to this silent pandemic credible.